Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kelly S Chien

Showing results (21-30 of 43) with videos related to

Pageof 5
Sort By:
American Journal of Hematology|September 4, 2020
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)Koji Sasaki, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, et al.
Leukemia Research|October 26, 2024
A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failureKelly S Chien, Juan Jose Rodriguez-Sevilla, Yesid Alvarado, et al.
Blood Advances|March 21, 2024
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasmAlex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, et al.
American Journal of Hematology|July 29, 2023
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failureSamuel Urrutia, Kelly S Chien, Ziyi Li, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
Cancer|December 2, 2022
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemiaAlexandre Bazinet, Faezeh Darbaniyan, Tapan M Kadia, et al.
Leukemia Research|August 23, 2024
Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysisDavid McCall, Tareq Abuasab, Juan Jose Rodriguez-Sevilla, et al.
Blood|July 13, 2023
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemiaJayastu Senapati, Samuel Urrutia, Sanam Loghavi, et al.
Hematological Oncology|August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndromeChristopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With OlutasidenibKelly S Chien, Sanam Loghavi, Koji Sasaki, et al.
Pageof 5

Showing results (21-30 of 43) with videos related to

Sort By:
Pageof 5
American Journal of Hematology|September 4, 2020
Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)Koji Sasaki, Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, et al.
Leukemia Research|October 26, 2024
A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failureKelly S Chien, Juan Jose Rodriguez-Sevilla, Yesid Alvarado, et al.
Blood Advances|March 21, 2024
Therapy-related chronic myelomonocytic leukemia does not have the high-risk features of a therapy-related neoplasmAlex Bataller, Georgina Gener-Ricos, Emmanuel Almanza-Huante, et al.
American Journal of Hematology|July 29, 2023
Performance of IPSS-M in patients with myelodysplastic syndrome after hypomethylating agent failureSamuel Urrutia, Kelly S Chien, Ziyi Li, et al.
Cancer|June 19, 2024
NPM1-mutated myeloid neoplasms are a unique entity not defined by bone marrow blast percentageGeorgina Gener-Ricos, Alex Bataller, Juan Jose Rodriguez-Sevilla, et al.
Cancer|December 2, 2022
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemiaAlexandre Bazinet, Faezeh Darbaniyan, Tapan M Kadia, et al.
Leukemia Research|August 23, 2024
Characteristics and outcomes of children, adolescent, and young adult patients with myelodysplastic neoplasms: A single-center retrospective analysisDavid McCall, Tareq Abuasab, Juan Jose Rodriguez-Sevilla, et al.
Blood|July 13, 2023
Venetoclax abrogates the prognostic impact of splicing factor gene mutations in newly diagnosed acute myeloid leukemiaJayastu Senapati, Samuel Urrutia, Sanam Loghavi, et al.
Hematological Oncology|August 29, 2018
Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndromeChristopher B Benton, Kelly S Chien, Ayalew Tefferi, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 30, 2025
Outcomes of Patients With IDH1-Mutated Myeloid Neoplasms Treated With OlutasidenibKelly S Chien, Sanam Loghavi, Koji Sasaki, et al.
Pageof 5